ASMB - Assembly Biosciences, Inc.
| Previous Close | 16.63 |
| Open | 16.51 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1000 |
| Day's Range | 16.40 - 17.61 |
| 52 Week Range | 8.13 - 25.68 |
| Volume | 210,213 |
| Avg. Volume | 648,703 |
| Market Cap | 458M |
| Beta (3Y Monthly) | 1.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.76 |
| Earnings Date | Nov 7, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.00 |
- Investor's Business Daily
Stock Upgrades: Assembly Biosciences Shows Rising Relative Strength
On Tuesday, Assembly Biosciences reached an important technical milestone, with its Relative Strength (RS) Rating climbing into the 80-plus percentile with an upgrade to 82, up from 78 the day before. When looking for the best stocks to buy and watch, keep a close on eye on relative price strength. Assembly Biosciences is not currently showing a potential buy point.
- GlobeNewswire
Assembly Biosciences Announces Plenary Lecture at HEP DART 2019
SOUTH SAN FRANCISCO, Calif., Dec. 06, 2019 -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting.
- GlobeNewswire
Assembly Biosciences Announces Presentation at Jefferies London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2019 -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting.
- GlobeNewswire
Data for Assembly Biosciences’ First and Second Generation HBV Core Inhibitors in Development for the Treatment of Chronic Hepatitis B Highlighted in Late-Breaker Poster Session at AASLD 2019
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, announced that data for its first and second generation HBV core inhibitors were highlighted during today’s late-breaker poster session at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®) in Boston, Massachusetts. The posters featured final 24-week results and interim long-term data from the Phase 2 studies of ABI-H0731 (731).
- Investor's Business Daily
Why It Could Soon Be Time To Take Profits In This Highflying Biotech Stock
Arrowhead Pharmaceuticals and Johnson & Johnson said Friday they eradicated nearly all traces of hepatitis B virus in a study — sending Arrowhead careening toward another record high.
- GlobeNewswire
Assembly Biosciences Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced a grant of inducement awards to its Chief Medical Officer, Luisa M. Stamm, MD, PhD on November 6, 2019. The Company granted Dr. Stamm non-qualified stock options to purchase 165,000 shares of the Company’s common stock with an exercise price of $16.11 per share, the closing price of Assembly’s common stock as reported by Nasdaq on November 6, 2019.
- GlobeNewswire
Assembly Biosciences Reports Third Quarter 2019 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif.,, Nov. 07, 2019 -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting.
- Zacks
Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for
Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Assembly Biosciences Appoints Luisa Stamm, MD, PhD, as Chief Medical Officer
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of Luisa Stamm, MD, PhD, as Chief Medical Officer. Dr. Stamm is an infectious disease specialist whose industry career has focused on the development of therapeutics for hepatitis C virus (HCV) and HIV.
- Insider Monkey
Hedge Funds Are Selling Assembly Biosciences Inc (ASMB)
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
- Zacks
Can Segmental Growth Aid Hologic (HOLX) in Q4 Earnings?
Developments in Breast Health and Molecular Diagnostics businesses are likely to have aided Hologic's (HOLX) performance in fourth-quarter fiscal 2019.
- Simply Wall St.
Estimating The Fair Value Of Assembly Biosciences, Inc. (NASDAQ:ASMB)
In this article we are going to estimate the intrinsic value of Assembly Biosciences, Inc. (NASDAQ:ASMB) by projecting...
- GlobeNewswire
Assembly Biosciences Appoints Thomas J. Russo as Chief Financial Officer
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of Thomas J. Russo as Chief Financial Officer. Mr. Russo brings 25 years of experience in the biotechnology and pharmaceutical industry, spanning finance and operations (including commercial planning and manufacturing), as well as equity research.
- Zacks
What's in Store for Thermo Fisher (TMO) in Q3 Earnings?
Developments in business segments are likely to have aided Thermo Fisher (TMO) in the third quarter.
- Zacks
Top Ranked Momentum Stocks to Buy for October 18th
Top Ranked Momentum Stocks to Buy for October 18th
- Investor's Business Daily
This Biotech Stock Nearly Doubled In Two Days On A Potential Hepatitis Cure
Shares of Assembly Biosciences rocketed in higher-than-average volume for a second day Thursday on excitement surrounding the biotech company's potential hepatitis B treatment.
- GlobeNewswire
Safety and Antiviral Activity of Assembly Biosciences’ First and Second Generation Core Inhibitor Candidates In the Treatment of Chronic Hepatitis B to be Featured in a Late Breaking Session at AASLD
Phase 2a studies of ABI-H0731 + nucleos(t)ide analogs (Nrtl) in HBeAg+ patients show faster and deeper declines in HBV DNA and RNA with combination than Nrtl alone, as well as.
- Zacks
Will Assembly Biosciences Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor Assembly Biosciences.
- Simply Wall St.
Investors Who Bought Assembly Biosciences (NASDAQ:ASMB) Shares A Year Ago Are Now Down 67%
Investing in stocks comes with the risk that the share price will fall. And unfortunately for Assembly Biosciences...
- GlobeNewswire
Assembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced a grant of inducement awards to its President and Chief Executive Officer, John McHutchison, AO, MD on August 6, 2019. The Company granted Dr. McHutchison non-qualified stock options to purchase 500,000 shares of the company’s common stock with an exercise price of $11.86 per share, the closing price of Assembly’s common stock as reported by Nasdaq on August 6, 2019.
- GlobeNewswire
Assembly Biosciences Announces Appointment of John McHutchison, AO, MD, as President and Chief Executive Officer
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of John McHutchison, AO, MD, as President and Chief Executive Officer effective August 6, 2019. Dr. McHutchison, who will also join Assembly’s Board of Directors, succeeds Derek Small, who co-founded Assembly Biosciences in 2014.
- Zacks
Assembly Biosciences (ASMB) Reports Q2 Loss, Lags Revenue Estimates
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 34.55% and -20.97%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Assembly Biosciences Reports Second Quarter 2019 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2019 -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting.
- Simply Wall St.
Does The Assembly Biosciences, Inc. (NASDAQ:ASMB) Share Price Tend To Follow The Market?
If you own shares in Assembly Biosciences, Inc. (NASDAQ:ASMB) then it's worth thinking about how it contributes to the...
